La vendita allo scoperto per Inogen dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Inogen. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Inogen (NASDAQ:INGN) Azioni, Report sulle vendite allo scoperto

Inogen

Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States.

Inogen Inc

Inogen, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ingn#NASDAQ">INGN</a>) is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid first-quarter 2024 performance and a strong product portfolio, seems justified. However, issues like stiff competition and forex volatility are major downsides.
The Zacks Rank #2 (Buy) company&#39;s shares have risen 106.4% year to date compared with 9.2% growth of the&nbsp;industry. The S&amp;P 500 has increased 17.7% during the same time frame.
The renowned provider of POCs has a market capitalization of $268.7 million. The company projects 56.6% growth for 2024 and expects to witness continued improvements in its business. Inogen&#39;s P/S ratio of 0.8X makes its valuation attractive compared with the industry&#39;s 3.1X.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/57/77823.jpg?v=1381474216" />
Image Source: Zacks Investment Research
Let us delve deeper.
High Prospects in the POC Space:&nbsp;We are optimistic about the POCs&#39; superiority over conventional oxygen therapy (known as the delivery model). Inogen primarily develops, manufactures and markets innovative POCs to deliver supplemental long-term oxygen therapy (LTOT) to patients suffering from chronic respiratory conditions.
INGN&#39;s proprietary Inogen One and Inogen Rove systems concentrate the air around the patient to offer a source of supplemental oxygen anytime, anywhere, with a battery that can be plugged into an outlet. Per a report by Data Bridge Market Research, the POCs market was valued at $1.58 billion in 2022 and is anticipated to reach $3.03 billion by 2030 at a CAGR of 8.5%.
Product Portfolio:&nbsp;We are optimistic about Inogen&#39;s expanding product portfolio. The company has received the FDA 510(k) clearance for the Inogen Rove 4, which is set to be launched soon. The Rove 4 will offer patients a new flow setting compared to the earlier versions, a service life of up to eight years and highest oxygen production. It is also the lightest POC in the market.
Inogen launched Rove 6 in the U.S. market in July 2023. The Inogen Rove 6 is the first POC with an expected service life of eight years.
Strong Q2 Results: Inogen&#39;s robust year-over-year uptick in domestic and international business-to-business sales buoys optimism. Solid year-over-year top and bottom-line performances were encouraging. Further, the expansion of the adjusted gross margin bodes well.
On the earnings call, management confirmed that targeting hospitals in addition to individual practitioners through its rental business gave earlier access to patients in their care pathway, increasing the duration over which INGN can receive payments. By expanding its scale, efficiency and throughput in the rental channel, Inogen expects to drive higher profitability over time.
The company is also seeing cost benefits in the form of lower sales and marketing expenses on the back of the recent exit of its third-party relationship in the rental channel. These factors raise optimism about the stock.
<h2>Risks</h2>
Stiff Competition:&nbsp;The LTOT market has intense industrial competition. Inogen faces competition from several POC producers and distributors as well as suppliers of other LTOT services, such as home delivery of oxygen cylinders or tanks. Given the relatively straightforward regulatory path in the oxygen therapy device manufacturing market, Inogen expects the industry to become increasingly competitive in the future.
Forex Volatility:&nbsp;The foreign market accounts for a sizeable amount of INGN&#39;s income. &nbsp;Management anticipates overseas revenues to continue to be erratic due to the distributor&#39;s size and timing. In the near future, INGN also expects unfavorable foreign exchange rates to hinder revenue growth since the U.S. dollar is increasing relative to the euro and other foreign currencies.
<h2>Estimate Trend</h2>
Inogen has been witnessing an improving estimate revision trend for 2024. In the past 60 days, the Zacks Consensus Estimate for its loss per share has narrowed 11.4% to $1.95.
The Zacks Consensus Estimate for 2024 revenues is pegged at $327 million, suggesting a 3.6% decline from the year-ago reported number.
<div class="chart_embed">
<h3>Inogen, Inc Price</h3>
<img alt="Inogen, Inc Price" src="https://staticx-tuner.zacks.com/images/charts/18/1726483416.png" style="height:251px; width:571px" title="" />
Inogen, Inc price | Inogen, Inc Quote
</div>
<h2>Key Picks</h2>
Some other top-ranked stocks in the broader medical space are Boston Scientific, AxoGen (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axgn#NASDAQ">AXGN</a>) and SiBone (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sibn#NASDAQ">SIBN</a>), each carrying a Zacks Rank #2 at present.
Boston Scientific&#39;s shares have risen 58.4% in the past year. Estimates for the company&#39;s earnings per share have remained constant at $2.40 for 2024 and $2.71 for 2025 in the past 30 days. BSX&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.2%. In the last reported quarter, it posted an earnings surprise of 6.9%.
Estimates for AxoGen&#39;s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 145% in the past year compared with the industry&#39;s growth of 15.5%. AXGN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%.
Estimates for SiBone&#39;s 2024 loss per share have remained constant at 89 cents in the past 30 days. Shares of the company have lost 30.4% in the past year against the industry&#39;s 15.5% growth. SIBN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.4%. In the last reported quarter, it delivered an earnings surprise of 15.4%.
<a href="https://www.zacks.com/stock/news/2336320/here-s-why-you-should-add-inogen-stock-to-your-portfolio-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2336320">To read this article on Zacks.com click here.</a>

Biotech

Earnings

Earnings Beats

News

Small Cap

Management

Markets

Analyst Ratings

Trading Ideas

General

AXGN

INGN

SIBN

Here's Why You Should Add Inogen Stock to Your Portfolio Now

Inogen, Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ingn#NASDAQ">INGN</a>) incurred an adjusted loss per share of 7 cents for the second quarter of 2024, narrower than the adjusted loss per share of 25 cents in the year-ago period. The Zacks Consensus Estimate was pegged at a loss of 54 cents per share.
GAAP loss per share for the quarter was 24 cents, better than the year-earlier loss of 42 cents per share.
<h3>Revenues in Detail</h3>
Inogen registered revenues of $88.8 million for the second quarter, up 6.1% year over year. The figure beat the Zacks Consensus Estimate by 7.8%.
At constant exchange rate (CER), total revenues for the reported quarter increased 6.2%.
Per management, the year-over-year uptick in the top line was primarily driven by higher international and domestic business-to-business sales. However, this was partially offset by lower direct-to-consumer sales and rental revenues.
<h3>Segmental Details</h3>
Inogen derives revenues from two sources &mdash; rental and sales.
Rental revenues for the reported quarter grossed $14.3 million, down 6.5% from the year-ago period, both on a reported basis and at CER. Per management, the decrease resulted from a higher mix of lower private payer reimbursement rates and higher rental revenue adjustments.
Sales revenues were $74.4 million, up 8.9% from the prior-year quarter.
<h3>Revenues by Region &amp; Category</h3>
Domestic business-to-business sales for second-quarter 2024 amounted to $21.3 million, up 16.5% on a year-over-year basis.
International business-to-business sales for the reported quarter amounted to $30.5 million, up 31.1% year over year on a reported basis and up 31.4% at CER.
Domestic direct-to-consumer sales decreased 15.6% year over year to $22.6 million in the quarter. Domestic direct-to-consumer rentals decreased 6.5% year over year to $14.3 million in the quarter.
<h3>Margins</h3>
For the quarter under review, Inogen&#39;s gross profit rose 25.6% from the year-ago period to $42.7 million. The gross margin expanded 740 basis points to 48.1%.
Sales and marketing expenses decreased 4.8% from the year-ago quarter to $25.6 million. Research and development expenses increased 30.2% year over year to $5.6 million. General and administrative expenses increased 27.4% to $18.6 million. Operating expenses of $49.8 million increased 8.7% year over year.
Operating loss totaled $7.1 million compared with the prior-year quarter&#39;s loss of $11.8 million.
<h3>Financial Position</h3>
Inogen exited the second quarter of 2024 with cash and cash equivalents of $98 million compared with $121.2 million at the end of the first quarter of 2024.
The company ended the quarter with no debt on its balance sheet.
Net cash provided by operating activities at the end of the second quarter of 2024 was $1.9 million against net cash used in operating activities of $2.3 million a year ago.
<h3>Guidance</h3>
Inogen provided its revenue outlook for 2024.
The company expects the metric to be between $325 million and $330 million. The Zacks Consensus Estimate currently stands at $322.3 million.
<h3>Our Take</h3>
Inogen exited the second quarter of 2024 with better-than-expected top and bottom-line numbers. The year-over-year improvement on both counts was encouraging. The robust year-over-year uptick in domestic and international business-to-business sales was impressive. The expansion of the gross margin also bodes well.
Inogen announced the launch of its latest Portable Oxygen Concentrator (POC) Rove 4 in the latter half of the year. Rove 4 introduces a fourth flow setting, offers up to eight years of service life and provides the highest oxygen production in the lightest POC on the market. These innovations align with its mission to enhance patient mobility and quality of life during oxygen therapy. With Rove 4, Inogen continues to lead the way in advanced, patient-focused oxygen therapy solutions.
However, the decline in domestic direct-to-consumer sales and rental revenues is concerning. Inogen continued to incur operating losses in the second quarter, which does not bode well.
<div class="chart_embed">
<h3>Inogen, Inc Price, Consensus and EPS Surprise</h3>
<img alt="Inogen, Inc Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/9f/1723036924.png" style="height:265px; width:574px" title="" />
Inogen, Inc price-consensus-eps-surprise-chart | Inogen, Inc Quote
</div>
<h3>Zacks Rank &amp; Key Picks</h3>
Currently, Inogen carries a Zacks Rank #3 (Hold).
Some top-ranked stocks in the broader medical space are&nbsp;Universal Health Service,&nbsp;Quest Diagnostics&nbsp;and&nbsp;ABM Industries. While Universal Health Service sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries carry a Zacks Rank #2 (Buy) each.
Universal Health Services has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Service has gained 41.1% compared with the industry&#39;s&nbsp;34.8% rise so far this year.
Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics shares have gained 3.7% so far this year compared with the&nbsp;industry&#39;s&nbsp;10.2% rise.
ABM Industries&#39; earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.
ABM&#39;s shares have risen 24.1% so far this year compared with the industry&#39;s&nbsp;11.9% increase.
<a href="https://www.zacks.com/stock/news/2318226/inogen-ingn-q2-earnings-beat-estimates-revenues-rise-y-y?cid=CS-BENZ-FT-analyst_blog|earnings_article-2318226">To read this article on Zacks.com click here.</a>

Guidance

Inogen Q2 Earnings Beat Estimates, Revenues Rise Y/Y

WIIM

Inogen shares are trading higher after the company reported better-than-expected Q2 financial results and issued FY24 revenue guidance above estimates.

Needham analyst Mike Matson reiterates Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) with a Hold.

Reiteration

Needham Reiterates Hold on Inogen

Inogen Sees FY24 Revenue $325M-$330M vs $322.75M Est.

Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.55) by 87.27 percent. The company reported quarterly sales of $88.765 million which beat the analyst consensus estimate of $82.500 million by 7.59 percent. This is a 6.13 percent increase over sales of $83.635 million the same period last year.

Inogen Q2 2024 Adj. EPS $(0.07) Beats $(0.55) Estimate, Sales $88.765M Beat $82.500M Estimate

Inogen shares are trading higher. The company reported Q2 financial results.

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.inogen.com&amp;esheet=54027913&amp;newsitemid=20240603365310&amp;lan=en-US&amp;anchor=Inogen%2C+Inc.&amp;index=1&amp;md5=f6e03ba6b1e78b7a2944d6e9c1fa0c24">Inogen, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>), a medical technology company offering innovative respiratory products for use in the homecare setting, today shared the results of a study published in the journal <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Flink.springer.com%2Fjournal%2F41030&amp;esheet=54027913&amp;newsitemid=20240603365310&amp;lan=en-US&amp;anchor=Pulmonary+Therapy&amp;index=3&amp;md5=f91e8e93d963795540ad6c2e9d5ecc6e">Pulmonary Therapy</a>, demonstrating the association of portable oxygen concentrators with increased survival and cost-effectiveness ratio when compared to other long-term oxygen therapies.
The study sourced data from the French national healthcare system database, the Système National des Données de Santé (SNDS). With a sample size of over 244,000 adult long-term oxygen therapy patients from 2013-2020, it is likely the largest retrospective claims database assessment study of long-term oxygen therapy to date. The results showed that portable oxygen concentrator (POC) use, either alone or in combination with other oxygen modalities, was associated with improved survival and similar healthcare resource use, such as hospitalizations and specialist visits, compared to stationary concentrators, compressed tanks and liquid oxygen. Additionally, based on the incremental cost-effectiveness ratio (ICER), POCs were cost-effective compared to stationary concentrators, compressed tanks, and liquid oxygen.

Inogen's Study Demonstrating The Association Of Portable Oxygen Therapy With Decreased Mortality And Increased Cost-Effectiveness Ratio Published In The Journal Pulmonary Therapy

Stifel analyst Mathew Blackman maintains Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) with a Hold and raises the price target from $6 to $7.

Price Target

Stifel Maintains Hold on Inogen, Raises Price Target to $7

Inogen Sees Q2 2024 Revenue $81M-$84M Vs $84.17M Estimate

Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.76) by 40.79 percent. This is a 28.57 percent increase over losses of $(0.63) per share from the same period last year. The company reported quarterly sales of $78.025 million which beat the analyst consensus estimate of $73.663 million by 5.92 percent. This is a 8.12 percent increase over sales of $72.162 million the same period last year.

Inogen Q1 2024 Adj EPS $(0.45) Beats $(0.76) Estimate, Sales $78.025M Beat $73.663M Estimate

<h3>Gainers</h3>
<ul>
<li>Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) shares increased by 14.9% to $0.85 during Tuesday's after-market session. The market value of their outstanding shares is at $421.4 million. The company's, Q1 earnings came out today. </li>
<li>Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) shares increased by 13.97% to $8.32. The market value of their outstanding shares is at $195.9 million. As per the press release, Q1 earnings came out today. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) shares rose 11.92% to $1.69. The market value of their outstanding shares is at $310.3 million. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) stock increased by 8.33% to $0.26. The company's market cap stands at $20.0 million. </li>
<li>EUDA Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EUDA#NASDAQ">EUDA</a>) stock increased by 7.99% to $1.89. The company's market cap stands at $46.5 million. </li>
<li>Atara Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) stock rose 7.84% to $0.65. The company's market cap stands at $78.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) shares declined by 34.1% to $7.34 during Tuesday's after-market session. The market value of their outstanding shares is at $454.6 million. As per the news, the Q1 earnings report came out today. </li>
<li>Inspire Medical Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) shares fell 15.87% to $206.67. The company's market cap stands at $6.2 billion. As per the press release, Q1 earnings came out today. </li>
<li>Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) stock declined by 15.71% to $23.73. The market value of their outstanding shares is at $166.8 million. As per the press release, Q1 earnings came out today. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) shares fell 14.93% to $1.14. The market value of their outstanding shares is at $5.1 million. </li>
<li>BiomX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) stock fell 12.51% to $0.35. The market value of their outstanding shares is at $19.3 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock declined by 8.28% to $1.22. The company's market cap stands at $13.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ATPC

ATRA

BSGM

CLOV

Euda Health Holdings Limited - Ordinary Shares

EUDA

INSP

NKTR

OGEN

PHGE

SMLR

TMCI

12 Health Care Stocks Moving In Tuesday's After-Market Session

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 100 points on Wednesday.
The Dow traded down 0.27% to 38,867.91 while the NASDAQ fell 0.50% to 15,954.75. The S&amp;P 500 also fell, dropping, 0.18% to 5,068.92.
Check This Out: <a href="https://www.benzinga.com/news/24/02/37361652/robinhood-shake-shack-and-2-other-stocks-insiders-are-selling"> Robinhood, Shake Shack And 2 Other Stocks Insiders Are Selling</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Real estate shares rose by 1.4% on Wednesday.
In trading on Wednesday, communication services shares fell by 0.8%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
ADT Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/adt#NYSE">ADT</a>) reported better-than-expected earnings for its fourth quarter on Wednesday.
ADT posted fourth-quarter fiscal 2023 sales decline of 7.2% year-on-year to $1.22 billion, missing the consensus of $1.44 billion. Adjusted EPS was 25 cents, beating the consensus of 4 cents.
ADT expects CSB segment revenue of 4.8 billion-$5.0 billion. The company expects adjusted EPS of $0.60 &ndash; $0.70, against consensus of $0.50.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Vivani Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vani#NASDAQ">VANI</a>) shares shot up 274% to $3.78 after the company announced preclinical data on weight loss effects for NPM-115 and disclosed that semaglutide is the active pharmaceutical ingredient in NPM-139.
Shares of Adial Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adil#NASDAQ">ADIL</a>) got a boost, surging 159% to $2.1917. Adial Pharmaceuticals secured new US patent covering lead product for alcohol use disorder.
vTv Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtvt#NASDAQ">VTVT</a>) shares were also up, gaining 117% to $18.05 after the company announced a $51 million private placement from healthcare-focused institutional investors and the JDRF T1D Fund.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Oragenics, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ogen#NYSE">OGEN</a>) shares dropped 42% to $1.42. Oragenics priced its public offering 1.4 million common shares at $1.50 per share for gross proceeds of $2.1 million.
Shares of Integral Ad Science Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ias#NASDAQ">IAS</a>) were down 42% to $9.92 after the company reported fourth-quarter financial results.
Inogen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ingn#NASDAQ">INGN</a>) was down, falling 35% to $6.08 following weak quarterly results.
Also Check This Out:<a href="https://www.benzinga.com/news/24/02/37334066/top-3-energy-stocks-that-could-sink-your-portfolio-in-q1"> Top 3 Energy Stocks That Could Sink Your Portfolio In Q1 </a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 0.3% to $78.65 while gold traded down 0.2% at $2,040.40.
Silver traded fell 0.5% to $22.645 on Wednesday while copper fell 0.3% to $3.8390.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mostly lower today. The eurozone&rsquo;s STOXX 600 fell 0.35%, London&rsquo;s FTSE 100 fell 0.76% while Spain&rsquo;s IBEX 35 Index fell 0.45% The German DAX gained 0.25% French CAC 40 rose 0.08% while Italy&rsquo;s FTSE MIB Index declined 0.27%.
The services confidence indicator in the Eurozone fell to 6 in February, the lowest in three months, while economic sentiment indicator fell to 95.4 in February. The consumer confidence indicator in the Eurozone increased by 0.6 points to a reading of -15.5 in February.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed lower on Wednesday, with Japan&rsquo;s Nikkei 225 falling 0.08%, Hong Kong&rsquo;s Hang Seng Index dipping 1.51%, China&rsquo;s Shanghai Composite Index tumbling 1.91% and India&rsquo;s S&amp;P BSE Sensex falling 1.08%.
Hong Kong&rsquo;s GDP increased by 4.3% year-over-year in the fourth quarter, up from a 4.1% increase in the prior period. The index of leading economic indicators in Japan was revised higher to 110.2 in December versus preliminary reading of 110, while index of coincident economic indicators was revised lower to 115.9 in December versus a flash reading of 116.2.
&nbsp;
<h3>Economics</h3>
&nbsp;
U.S. mortgage applications fell by 5.6% on the week ending Feb. 23.
The U.S. economy grew an annualized 3.2% in the fourth quarter, versus a 4.9% rate in the previous quarter.
The U.S. trade deficit in goods rose to $90.20 billion in January versus a revised $87.89 billion in the prior month.
U.S. wholesale inventories declined by 0.1% month-over-month in January following a 0.4% increase a month ago.
U.S. crude oil inventories increased by 4.199 million barrels in the week ending Feb. 23, versus market estimates of a 2.743 million gain, the EIA said.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/02/37356403/cramer-says-this-ai-stock-is-just-an-nvidia-play-prefers-this-stock-over-anheuser-busch"> Cramer Says This AI Stock Is Just An Nvidia Play, Prefers This Stock Over Anheuser-Busch </a>

Penny Stocks

Eurozone

Commodities

Global

Intraday Update

ADIL

VANI

VTVT

S&P 500 Edges Lower; ADT Posts Upbeat Earnings

Shares of Bumble Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bmbl#NASDAQ">BMBL</a>) fell sharply during Wednesday&rsquo;s session <a href="https://www.benzinga.com/news/earnings/24/02/37349026/bumble-reports-q4-results-eps-miss-revenue-miss-workforce-reductions">following weak quarterly results</a>.
Bumble reported quarterly losses of 19 cents per share which missed the analyst consensus estimate of 12 cents per share. The company reported quarterly sales of $273.64 million which missed the analyst consensus estimate of $275.29 million.
Bumble shares dipped 11.6% to $11.65 on Wednesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Vivani Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vani#NASDAQ">VANI</a>) shares jumped 289% to $3.93 after the company announced preclinical data on weight loss effects for NPM-115 and disclosed that semaglutide is the active pharmaceutical ingredient in NPM-139.</li>
<li>Adial Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adil#NASDAQ">ADIL</a>) climbed 190% to $2.4598. Adial Pharmaceuticals secured new US patent covering lead product for alcohol use disorder.</li>
<li>vTv Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtvt#NASDAQ">VTVT</a>) gained 112% to $17.65 after the company announced a $51 million private placement from healthcare-focused institutional investors and the JDRF T1D Fund.</li>
<li>Bit Brother Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bets#NASDAQ">BETS</a>) shares rose 63.7% to $4.0750.</li>
<li>Beyond Meat, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bynd#NASDAQ">BYND</a>) climbed 45% to $10.90 as the company reported stronger-than-expected sales for its fourth quarter.</li>
<li>Incannex Healthcare Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ixhl#NASDAQ">IXHL</a>) gained 43.6% to $6.06 after the company announced its Psi-GAD1 trial met its primary endpoint.</li>
<li>Bandwidth Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/band#NASDAQ">BAND</a>) surged 43.3% to $17.41 after the company reported better-than-expected fourth quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Imunon, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imnn#NASDAQ">IMNN</a>) climbed 38% to $0.98.</li>
<li>Applied Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aplt#NASDAQ">APLT</a>) surged 36% to $7.59 after the company announced FDA acceptance and priority review of the NDA for govorestat for the treatment of Classic Galactosemia. The company also announced a $100 million private placement.</li>
<li>Movella Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mvla#NASDAQ">MVLA</a>) gained 33.5% to $0.33.</li>
<li>LifeStance Health Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lfst#NASDAQ">LFST</a>) gained 31.5% to $8.81 following strong quarterly sales.</li>
<li>AirNet Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ante#NASDAQ">ANTE</a>) rose 31.3% to $1.05. AirNet announced changes in senior management team.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/psny#NASDAQ">PSNY</a>) rose 29.9% to $1.9350. Polestar secured $1 billion external funding.</li>
<li>Editas Medicine, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/edit#NASDAQ">EDIT</a>) gained 27.7% to $11.31 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>TG Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tgtx#NASDAQ">TGTX</a>) jumped 27.2% to $17.69 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Qurate Retail, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qrtea#NASDAQ">QRTEA</a>) rose 22% to $1.71 after the company reported fourth-quarter financial results.</li>
<li>B&amp;G Foods, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bgs#NYSE">BGS</a>) gained 21.4% to $11.41 after the company reported better-than-expected fourth-quarter financial results and issued FY24 revenue guidance.</li>
<li>Flywire Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flyw#NASDAQ">FLYW</a>) gained 20% to $29.40 after the company reported better-than-expected fourth quarter financial results.</li>
<li>Flywire Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flyw#NASDAQ">FLYW</a>) climbed 17.6% to $28.84 after the company reported better-than-expected fourth quarter financial results.</li>
<li>The Vita Coco Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coco#NASDAQ">COCO</a>) surged 17.3% to $26.32 after the company reported better-than-expected fourth-quarter financial results and issued FY24 net sales guidance.</li>
<li>J-Long Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jl#NASDAQ">JL</a>) gained 17.2% to $18.90.</li>
<li>Revolve Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rvlv#NYSE">RVLV</a>) rose 16% to $20.28 as the company reported upbeat results for its fourth quarter on Tuesday.</li>
<li>Nauticus Robotics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kitt#NASDAQ">KITT</a>) gained 15.9% to $0.3549.</li>
<li>Life Time Group Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lth#NYSE">LTH</a>) gained 15.3% to $14.32 after the company reported better-than-expected fourth quarter financial results and issued first-quarter revenue guidance above estimates.</li>
<li>Ventyx Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtyx#NASDAQ">VTYX</a>) shares jumped 15% to $6.96 in pre-market trading following fourth-quarter results.</li>
<li>Connexa Sports Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cnxa#NASDAQ">CNXA</a>) shares jumped 14.3% to $0.27.</li>
<li>ACM Research, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acmr#NASDAQ">ACMR</a>) rose 13.6% to $24.75 in pre-market trading after the company reported better-than-expected fourth-quarter FY23 results.</li>
<li>Vipshop Holdings Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vips#NYSE">VIPS</a>) gained 12.4% to $19.49 after the company reported better-than-expected fourth quarter financial results.</li>
<li>MicroStrategy Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mstr#NASDAQ">MSTR</a>) climbed 10.9% to $967.01.</li>
<li>Chart Industries, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gtls#NASDAQ">GTLS</a>) rose 10.5% to $145.33 after the company reported mixed fourth quarter financial results and issued FY24 adjusted EPS guidance above estimates.</li>
<li>Assured Guaranty Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ago#NYSE">AGO</a>) gained 9.8% to $94.11 following fourth quarter financial results.</li>
<li>eBay Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ebay#NASDAQ">EBAY</a>) rose 8.4% to $48.15 after the company reported better-than-expected fourth quarter financial results.</li>
<li>ADT Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/adt#NYSE">ADT</a>) climbed 7.2% to $7.00 following upbeat earnings.</li>
<li>Advance Auto Parts, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aap#NYSE">AAP</a>) gained 7.1% to $69.32 fourth quarter financial results.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Oragenics, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ogen#NYSE">OGEN</a>) shares fell 43.3% to $1.39. Oragenics priced its public offering 1.4 million common shares at $1.50 per share for gross proceeds of $2.1 million.</li>
<li>Integral Ad Science Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ias#NASDAQ">IAS</a>) fell 40.2% to $1.39 after the company reported fourth-quarter financial results.</li>
<li>Charge Enterprises, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crge#NASDAQ">CRGE</a>) fell 36.8% to $0.0379.</li>
<li>Palatin Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ptn#NYSE">PTN</a>) fell 34.8% to $2.5880 after the company reported results of PL9643 MELODY-1 pivotal Phase 3 clinical trial in patients with dry eye disease.</li>
<li>Inogen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ingn#NASDAQ">INGN</a>) dipped 31.2% to $6.43 following weak results.</li>
<li>Eventbrite, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/eb#NYSE">EB</a>) fell 30.2% to $5.81 after the company reported mixed fourth-quarter financial results.</li>
<li>Solarmax Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smxt#NASDAQ">SMXT</a>) shares fell 27.5% to $5.81. SolarMax Technology announced pricing of initial public offering and listing on Nasdaq.</li>
<li>Novavax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvax#NASDAQ">NVAX</a>) dipped 27% to $4.4000 after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter revenue guidance below estimates.</li>
<li>Lemonade, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lmnd#NYSE">LMND</a>) shares declined 26.1% to $16.04 after the company reported fourth-quarter financial results.</li>
<li>Vicarious Surgical Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rbot#NYSE">RBOT</a>) fell 24% to $0.4099 after jumping 57% on Tuesday.</li>
<li>Ocean Biomedical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocea#NASDAQ">OCEA</a>) dipped 21.9% to $1.53.</li>
<li>Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) fell 21.8% to $1.00.</li>
<li>3D Systems Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ddd#NYSE">DDD</a>) fell 21.6% to $4.10 following weak fourth-quarter financial results.</li>
<li>Nerdy, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nrdy#NYSE">NRDY</a>) fell 21% to $2.4099 following fourth-quarter financial results.</li>
<li>Vertex Energy, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vtnr#NYSE">VTNR</a>) shares dipped 20.7% to $1.3310 after posting a fourth-quarter loss.</li>
<li>Alignment Healthcare, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alhc#NASDAQ">ALHC</a>) fell 17.5% to $5.71 after the company reported worse-than-expected fourth-quarter GAAP EPS results.</li>
<li>Progyny, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pgny#NASDAQ">PGNY</a>) fell 17.2% to $33.79 after the company reported mixed fourth-quarter financial results.</li>
<li>The Boston Beer Company, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sam#NYSE">SAM</a>) dipped 17.1% to $306.80 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Payoneer Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/payo#NASDAQ">PAYO</a>) fell 15.6% to $4.69 after the company issued FY24 revenue guidance below estimates.</li>
<li>Concentrix Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cnxc#NASDAQ">CNXC</a>) fell 15.3% to $70.25.</li>
<li>Urban Outfitters, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/urbn#NASDAQ">URBN</a>) shares declined 15% to $40.08 after the company reported fourth-quarter financial results.</li>
<li>Hyster-Yale Materials Handling, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hy#NYSE">HY</a>) fell 14.1% to $60.20 following fourth-quarter results.</li>
<li>The E.W. Scripps Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ssp#NASDAQ">SSP</a>) fell 12.2% to $4.1050 after the company reported mixed fourth-quarter financial results.</li>
<li>Luminar Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lazr#NASDAQ">LAZR</a>) dipped 10% to $2.25 following downbeat quarterly results.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rxrx#NASDAQ">RXRX</a>) shares fell 9.1% to $14.10 after the company reported mixed fourth-quarter financial results.</li>
<li>Baidu, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bidu#NASDAQ">BIDU</a>) fell 7.1% to $104.42 after the company reported financial Q4 results.</li>
<li>Macy&#39;s, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/m#NYSE">M</a>) fell 4.8% to $18.99.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/02/37366156/snowflake-gears-up-for-q4-print-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-cal"> Snowflake Gears Up For Q4 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call </a>

ACMR

ALHC

ANTE

APLT

BAND

BETS

BIDU

BMBL

BYND

CONNEXA SPORTS TECH INC by Connexa Sports Technologies Inc.

CNXA

CNXC

COCO

CRGE

EBAY

EDIT

FLYW

GTLS

IFBD

IMNN

IXHL

KITT

LAZR

LFST

LMND

MSTR

MVLA

NRDY

NVAX

OCEA

PAYO

PGNY

PSNY

QRTEA

RBOT

RVLV

RXRX

SMXT

TGTX

URBN

VIPS

VTNR

VTYX

Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Inogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>), a medical technology company, reported fourth-quarter 2023 revenues of $75.90 million, missing the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $76.99 million</a>.
Fourth quarter total revenue fell from $88.1 million in the fourth quarter of 2022. This was primarily due to a decrease in domestic business-to-business and direct-to-consumer sales, partially offset by <a href="https://www.benzinga.com/pressreleases/24/02/b37347241/inogen-announces-fourth-quarter-and-full-year-2023-financial-results" target="_blank" rel="noreferrer noopener">higher rental revenue</a>.
Inogen reported an adjusted EPS loss of $(0.83). While the company missed the consensus of $(0.62), it reported higher than the $(0.57) reported a year ago.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37166065/competitor-exit-a-boom-for-respiratory-device-focused-inogen-earns-analyst-upgrade" target="_blank" rel="noreferrer noopener">Competitor Exit A Boom For Respiratory Device-Focused Inogen, Earns Analyst Upgrade</a>.
Guidance:&nbsp;Inogen expects first quarter 2024 revenue of $73 million-$74 million versus the consensus of $80.63 million.
William Blair acknowledges the uncertainties in international tenders and the company&#8217;s commercial strategy adjustments, such as discontinuing a third-party rental partnership.&nbsp;
Despite these challenges, the analyst writes that the provided guidance is realistic and potentially surpassable under the new management team.&nbsp;
There are positive indicators of market improvement and Inogen&#8217;s enhanced market position, particularly with a significant competitor exiting.
Specific market share figures for Respironics before its January exit from the POC market were not disclosed. Inogen is described as a market leader with an estimated 40%-50% share. 
The departure of the competitor has created an opportunity for Inogen to capture additional market share (estimated at 15%-25% for Respironics). Although this potential benefit is not included in the first-quarter guidance, management has indicated early interest from some HME customers.
William Blair reiterates the&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/INGN/analyst-ratings" rel="noreferrer noopener">Outperform rating in the stock</a>.
Price Action:&nbsp;INGN shares are down 31.1% at $6.44 on the last check Wednesday.

Health Care

Why Is Inogen Stock Plummeting Today?

<h3>Gainers</h3>
<ul>
<li>Vivani Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) stock increased by 314.4% to $4.19 during Wednesday's regular session. The company's market cap stands at $213.5 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock moved upwards by 157.73% to $2.25. The market value of their outstanding shares is at $3.7 million. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) shares moved upwards by 105.88% to $17.5. The market value of their outstanding shares is at $35.6 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares increased by 40.27% to $0.71. The company's market cap stands at $6.6 million. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares rose 36.61% to $0.97. The company's market cap stands at $9.1 million. </li>
<li>G1 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTHX#NASDAQ">GTHX</a>) stock rose 35.2% to $3.25. The market value of their outstanding shares is at $168.2 million. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) stock declined by 42.9% to $1.4 during Wednesday's regular session. The company's market cap stands at $4.3 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock declined by 37.41% to $2.48. The market value of their outstanding shares is at $40.0 million. </li>
<li>Inogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INGN#NASDAQ">INGN</a>) stock declined by 35.44% to $6.03. The market value of their outstanding shares is at $140.5 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) stock decreased by 27.41% to $4.37. The market value of their outstanding shares is at $519.1 million. As per the news, the Q4 earnings report came out today. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) shares fell 24.41% to $0.41. The market value of their outstanding shares is at $71.3 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock fell 23.47% to $1.5. The company's market cap stands at $51.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GTHX

12 Health Care Stocks Moving In Wednesday's Intraday Session

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 50 points on Wednesday.
The Dow traded down 0.19% to 38,899.92 while the NASDAQ fell 0.31% to 15,985.25. The S&amp;P 500 also fell, dropping, 0.11% to 5,072.67.
Check This Out: <a href="https://www.benzinga.com/news/24/02/37361652/robinhood-shake-shack-and-2-other-stocks-insiders-are-selling"> Robinhood, Shake Shack And 2 Other Stocks Insiders Are Selling</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Real estate shares rose by 1.1% on Wednesday.
In trading on Wednesday, health care shares fell by 0.8%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
U.S. crude oil inventories increased by 4.199 million barrels in the week ending Feb. 23, versus market estimates of a 2.743 million gain, the EIA said.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Vivani Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vani#NASDAQ">VANI</a>) shares shot up 301% to $4.05 after the company announced preclinical data on weight loss effects for NPM-115 and disclosed that semaglutide is the active pharmaceutical ingredient in NPM-139.
Shares of Adial Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adil#NASDAQ">ADIL</a>) got a boost, surging 164% to $2.2350. Adial Pharmaceuticals secured new US patent covering lead product for alcohol use disorder.
vTv Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtvt#NASDAQ">VTVT</a>) shares were also up, gaining 136% to $19.61 after the company announced a $51 million private placement from healthcare-focused institutional investors and the JDRF T1D Fund.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Oragenics, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ogen#NYSE">OGEN</a>) shares dropped 43% to $1.40. Oragenics priced its public offering 1.4 million common shares at $1.50 per share for gross proceeds of $2.1 million.
Shares of Integral Ad Science Holding Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ias#NASDAQ">IAS</a>) were down 41% to $10.15 after the company reported fourth-quarter financial results.
Inogen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ingn#NASDAQ">INGN</a>) was down, falling 35% to $6.12 following weak quarterly results.
Also Check This Out:<a href="https://www.benzinga.com/news/24/02/37334066/top-3-energy-stocks-that-could-sink-your-portfolio-in-q1"> Top 3 Energy Stocks That Could Sink Your Portfolio In Q1 </a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 0.6% to $78.38 while gold traded down 0.1% at $2,043.80.
Silver traded fell 0.5% to $22.645 on Wednesday while copper fell 0.3% to $3.8390.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mostly lower today. The eurozone&rsquo;s STOXX 600 fell 0.35%, London&rsquo;s FTSE 100 fell 0.76% while Spain&rsquo;s IBEX 35 Index fell 0.45% The German DAX gained 0.25% French CAC 40 rose 0.08% while Italy&rsquo;s FTSE MIB Index declined 0.27%.
The services confidence indicator in the Eurozone fell to 6 in February, the lowest in three months, while economic sentiment indicator fell to 95.4 in February. The consumer confidence indicator in the Eurozone increased by 0.6 points to a reading of -15.5 in February.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed lower on Wednesday, with Japan&rsquo;s Nikkei 225 falling 0.08%, Hong Kong&rsquo;s Hang Seng Index dipping 1.51%, China&rsquo;s Shanghai Composite Index tumbling 1.91% and India&rsquo;s S&amp;P BSE Sensex falling 1.08%.
Hong Kong&rsquo;s GDP increased by 4.3% year-over-year in the fourth quarter, up from a 4.1% increase in the prior period. The index of leading economic indicators in Japan was revised higher to 110.2 in December versus preliminary reading of 110, while index of coincident economic indicators was revised lower to 115.9 in December versus a flash reading of 116.2.
&nbsp;
<h3>Economics</h3>
&nbsp;
U.S. mortgage applications fell by 5.6% on the week ending Feb. 23.
The U.S. economy grew an annualized 3.2% in the fourth quarter, versus a 4.9% rate in the previous quarter.
The U.S. trade deficit in goods rose to $90.20 billion in January versus a revised $87.89 billion in the prior month.
U.S. wholesale inventories declined by 0.1% month-over-month in January following a 0.4% increase a month ago.
U.S. crude oil inventories increased by 4.199 million barrels in the week ending Feb. 23, versus market estimates of a 2.743 million gain, the EIA said.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/02/37356403/cramer-says-this-ai-stock-is-just-an-nvidia-play-prefers-this-stock-over-anheuser-busch"> Cramer Says This AI Stock Is Just An Nvidia Play, Prefers This Stock Over Anheuser-Busch </a>

Nasdaq Down 50 Points; US Crude Stocks Rise By 4.2M Barrels

Inogen Shares Resume Trade

Offerpad Solutions: Now Is The Time To Go Against The Crowd

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Investing in small-cap stocks can be a gateway to high returns, mainly when these companies exhibit strong growth fundamentals and strategic market positioning. Here, the focus is on three stocks to buy under $10. The fundamentals behind these companies may diversify portfolios with high potential. These companies&rsquo; financial performance and strategic initiatives explain why these small-cap stocks&nbsp;are poised&nbsp;for high gains.



The first one has consistently demonstrated impressive top-line growth, driven by its diversified financial services. The second one improves healthcare equipment. Its sales strategies have been refined to achieve solid domestic and international revenue increases. Finally, the third one advances its innovative drug pipeline while securing significant financial support. These companies represent different sectors but share a common thread of&nbsp;solid&nbsp;fundamentals and strategic growth. These factors make them sharp investments in the small-cap space.



<h2>SoFi Technologies (SOFI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/10/sofi1600-1-300x169.png" alt="SoFi Technologies, Inc logo with stock market chart background. is an American online personal finance company and online bank."><div>Source: Poetra.RH / Shutterstock.com</div></div>SoFi Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/sofi-stock-quote/">SOFI</a>) offers loans, banking and investment services. In Q1 2024, SoFi reported adjusted net revenue of $581 million. This means a&nbsp;<a href="https://investors.sofi.com/news/news-details/2024/SoFi-Technologies-Reports-Q1-2024-Net-Revenue-of-645-Million-and-Net-Income-of-88-Million-Marking-Second-Consecutive-Quarter-of-GAAP-Profitability/default.aspx" target="_blank">26% year-over-year (YoY)</a>&nbsp;increase. Here, that growth trend has been consistent. 



The company attained over 25% growth for 12 consecutive quarters. This sustained growth points to a solid business model capable of scaling and adapting to market demands. The increasing contribution of the financial services segment to SoFi&rsquo;s overall revenue marks a notable trend. The Financial Services segment grew its top line by 86% YoY, resulting in <a href="https://investors.sofi.com/news/news-details/2024/SoFi-Technologies-Reports-Q1-2024-Net-Revenue-of-645-Million-and-Net-Income-of-88-Million-Marking-Second-Consecutive-Quarter-of-GAAP-Profitability/default.aspx" target="_blank">$151 million</a>&nbsp;in Q1 2024.&nbsp;



Further, this progress points to&nbsp;solid&nbsp;operating leverage, with only an 8% increase in expenses driving high revenue growth. SoFi Money has solid growth, with 3.9 million accounts, up 61% YoY. The average account balance and transaction volume also increased, with debit transaction volume exceeding $1.9 billion, up over 150% YoY. Direct deposit members drive high-quality deposits with a median&nbsp;<a href="https://seekingalpha.com/article/4687230-sofi-technologies-inc-sofi-q1-2024-earnings-call-transcript" target="_blank">FICO score of 744</a>, which presents ample cross-selling opportunities.



Finally, the company&rsquo;s solid top-line growth, constant quarters and strategic expansion solidify its presence on the top stocks to buy under $10.



<h2>Inogen (INGN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/healthcare1600d-300x169.jpg" alt="Healthcare professional in green scrubs standing with arms crossed."><div>Source: Shutterstock</div></div>Inogen (NASDAQ:<a href="https://investorplace.com/stock-quotes/ingn-stock-quote/">INGN</a>) leads the creation and promotion of cutting-edge respiratory treatment. The business has made considerable efforts to enhance its rental and sales tactics, with progressive outcomes. The company&rsquo;s <a href="https://d1io3yog0oux5.cloudfront.net/_3386f48ee1a71d9797418b34ed094cb5/inogen/news/2024-05-07_Inogen_Announces_First_Quarter_2024_Financial_229.pdf" target="_blank">$78 million Q1 2024</a> top line represents a 3% sequential gain and an 8% YoY increase. This expansion shows how Inogen&rsquo;s initiatives are being implemented successfully and that market demand has grown high for its products.
Domestic business-to-business revenue increased by&nbsp;<a href="https://d1io3yog0oux5.cloudfront.net/_3386f48ee1a71d9797418b34ed094cb5/inogen/news/2024-05-07_Inogen_Announces_First_Quarter_2024_Financial_229.pdf" target="_blank">31.3%</a>. It grew from $12.6 million to $16.5 million. Increased demand from current resellers and acquisition of new clients mainly drove this expansion. Further, this highlights successful efforts to expand market presence and strengthen partnerships.&nbsp;
Moreover, international business-to-business revenue had a high&nbsp;<a href="https://d1io3yog0oux5.cloudfront.net/_3386f48ee1a71d9797418b34ed094cb5/inogen/db/389/3854/transcript/CORRECTED+TRANSCRIPT++Inogen%2C+Inc.%28INGN-US%29%2C+Q1+2024+Earnings+Call%2C+7-May-2024+5+00+PM+ET.pdf" target="_blank">37.2% increase</a>&nbsp;to $26 million from $19 million in Q1 2023.&nbsp;This&nbsp;reflects the company&rsquo;s success in global market penetration. Indeed, the higher sales volumes to existing customers reflect strong ongoing relationships and customer satisfaction. For Q2 2024, Inogen expects total sales to be between $81 million and $84 million, indicating continued positive momentum and the execution of strategic priorities.


Overall, Inogen&rsquo;s progressive refinement of sales and rental strategies makes it a top mark on the list of top stocks to buy under $10.



<h2>Scynexis (SCYX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/pharmaceutical1600-300x169.png" alt="pharmaceutical industry. Production line machine conveyor with glass bottles ampoules at factory"><div>Source: Dmitry Kalinovsky / Shutterstock.com</div></div>Scynexis (NASDAQ:<a href="https://investorplace.com/stock-quotes/scyx-stock-quote/">SCYX</a>) is a pharma business. Phase I trials for&nbsp;<a href="https://ir.scynexis.com/news-events/press-releases/detail/334/scynexis-presented-preclinical-data-on-second-generation" target="_blank">SCY-247</a>&nbsp;will begin later in 2024, indicating that the business is managing its drug development pipeline well. The National Institute of Health&rsquo;s financial backing further validates the drug&rsquo;s potential efficacy and the company&rsquo;s capacity to obtain non-dilutive financing sources. 



Clinical&nbsp;study&nbsp;findings for the CARES, FURI and NATURE studies&nbsp;are scheduled&nbsp;to be delivered to GSK (NYSE:<a href="https://investorplace.com/stock-quotes/gsk-stock-quote/">GSK</a>) by the middle of 2024. A&nbsp;<a href="https://ir.scynexis.com/news-events/press-releases/detail/335/scynexis-reports-first-quarter-2024-financial-resultsand" target="_blank">$10 million payment</a>&nbsp;to Scynexis will be made in response to this milestone.&nbsp;This&nbsp;demonstrates the company&rsquo;s fundamental capacity to hit&nbsp;important&nbsp;development goals.



Moreover, a strong cash position of $94.2 million ensures that Scynexis can sustain its research without the immediate need for additional funding. The ability to generate revenue through strategic licensing agreements (like $1.4 million from GSK) points to a diversified and stable revenue model. The company achieved an&nbsp;<a href="https://ir.scynexis.com/news-events/press-releases/detail/335/scynexis-reports-first-quarter-2024-financial-resultsand" target="_blank">EPS of 1 cent per share</a>&nbsp;in Q1 2024, against a negative EPS of 71 cents in Q1 2023. This turnaround from a significant loss to a modest profit reflects sharp operational improvement.



Overall, the company&rsquo;s pipeline advancement into Phase I trials, strong cash position and strategic licensing agreements support its presence among top stocks to buy under $10.



On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, Yiannis Zourmpanos did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Yiannis Zourmpanos is the founder of Yiazou Capital Research, a stock-market research platform designed to elevate the due diligence process through in-depth business analysis.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/07/3-stocks-under-10-with-the-potential-for-massive-gains/">3 Stocks Under $10 With the Potential for Massive Gains</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Stocks Under $10 With the Potential for Massive Gains

Energy Vault: An Opportunity For Contrarian Value Investors

Inogen (INGN) has provided an update. Inogen, Inc. has confirmed that Jason Somer, the Executive Vice President, General Counsel, and Secretary, wi...

Inogen Announces Executive Departure and Transition Plan

Inogen GAAP EPS of -$0.24 beats by $0.30, revenue of $88.8M beats by $6.3M

Inogen, Inc. (INGN) Q2 2024 Earnings Call Transcript

In a report released today, Michael Matson from Needham maintained a Hold rating on Inogen (INGN – Research Report). The company's shares closed ye...

Needham Remains a Hold on Inogen (INGN)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning!



Earnings reports, an acquisition deal and more are behind today&rsquo;s biggest stock market movements.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Zhongchao (NASDAQ:<a href="https://investorplace.com/stock-quotes/zcmd-stock-quote/">ZCMD</a>) stock is rocketing 78% higher alongside heavy pre-market trading.</li>



<li>G1 Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/gthx-stock-quote/">GTHX</a>) shares are soaring more than 65% on <a href="https://finance.yahoo.com/news/pharmacosmos-group-acquire-g1-therapeutics-102900391.html">an acquisition deal</a>.</li>



<li>Richtech Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rr-stock-quote/">RR</a>) stock is surging over 48% with strong early morning trading.</li>



<li>AlphaVest Acquisition Corp &ndash; Right (NASDAQ:<a href="https://investorplace.com/stock-quotes/atmvr-stock-quote/">ATMVR</a>) shares are gaining more than 46% this morning.</li>



<li>Inogen (NASDAQ:<a href="https://investorplace.com/stock-quotes/ingn-stock-quote/">INGN</a>) stock is increasing over 31% with its <a href="https://www.nasdaq.com/press-release/inogen-announces-second-quarter-2024-financial-results-2024-08-06">Q2 earnings report</a>.</li>



<li>Upstart (NASDAQ:<a href="https://investorplace.com/stock-quotes/upst-stock-quote/">UPST</a>) shares are rising more than 25% after <a href="https://finance.yahoo.com/news/upstart-holdings-inc-upst-reports-221010260.html">reporting a Q2 revenue beat</a>.</li>



<li>Lumen Technologies (NYSE:<a href="https://investorplace.com/stock-quotes/lumn-stock-quote/">LUMN</a>) stock is heading over 24% higher <a href="https://www.fool.com/earnings/call-transcripts/2024/08/06/lumen-technologies-lumn-q2-2024-earnings-call-tran/">with its latest earnings</a>.</li>



<li>Veracyte (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcyt-stock-quote/">VCYT</a>) shares are climbing close to 22% after <a href="https://www.nasdaq.com/press-release/veracyte-announces-second-quarter-2024-financial-results-2024-08-06">announcing its Q2 results</a>.</li>



<li>Direxion Shares ETF Trust Direxion Daily Electric and Autonomous Vehicles Bull 2X Shares (NYSEARCA:<a href="https://investorplace.com/stock-quotes/evav-stock-quote/">EVAV</a>) are jumping more than 19% this morning.</li>



<li>Shopify (NYSE:<a href="https://investorplace.com/stock-quotes/shop-stock-quote/">SHOP</a>) stock is up 18% on <a href="https://za.investing.com/news/stock-market-news/shopify-stock-soars-on-solid-q2-report-issues-q3-guidance-432SI-3275444">solid Q2 earnings results</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Scorpius (NYSEMKT:<a href="https://investorplace.com/stock-quotes/scpx-stock-quote/">SCPX</a>) shares are crashing over 79% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318500722&amp;type=PDF&amp;symbol=SCPX&amp;cdn=70e2821112bdd2f31adb78fe13cd4e38&amp;companyName=Scorpius+Holdings+Inc.&amp;formType=FWP&amp;formDescription=Filing+under+Securities+Act+Rules+163%2F433+of+free+writing+prospectuses&amp;dateFiled=2024-08-07">proposed public offering</a>.</li>



<li>Talis Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/tlis-stock-quote/">TLIS</a>) stock is plummeting more than 47% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318499549&amp;type=PDF&amp;symbol=TLIS&amp;cdn=2a3bd0b3e041ab6a71139ad061fc0a12&amp;companyName=Talis+Biomedical+Corporation&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-08-06">on restructuring updates</a>.</li>



<li>DZS (NASDAQ:<a href="https://investorplace.com/stock-quotes/dzsi-stock-quote/">DZSI</a>) shares are diving over 45% as it <a href="https://www.nasdaq.com/press-release/dzs-receives-expected-delisting-notice-nasdaq-2024-08-06">prepares for a delisting notice</a>.</li>



<li>Stem (NYSE:<a href="https://investorplace.com/stock-quotes/stem-stock-quote/">STEM</a>) stock is tumbling 38% <a href="https://finance.yahoo.com/news/stem-inc-stem-reports-q2-221513320.html">on Q2 misses</a>.</li>



<li>Nevro (NYSE:<a href="https://investorplace.com/stock-quotes/nvro-stock-quote/">NVRO</a>) shares are taking a more than 37% beating after <a href="https://www.marketwatch.com/story/nevro-shares-fall-21-cuts-2024-revenue-outlook-75cf8aa9?mod=newsviewer_click">cutting its revenue outlook</a>.</li>



<li>Emergent BioSolutions (NYSE:<a href="https://investorplace.com/stock-quotes/ebs-stock-quote/">EBS</a>) stock is sliding over 35% <a href="https://www.stocktitan.net/news/EBS/emergent-bio-solutions-reports-second-quarter-2024-financial-h8fhmjurwquo.html">alongside its Q2 results</a>.</li>



<li>VBI Vaccines (NASDAQ:<a href="https://investorplace.com/stock-quotes/vbiv-stock-quote/">VBIV</a>) shares are dropping more than 34% <a href="https://investorplace.com/2024/08/why-is-vbi-vaccines-vbiv-stock-up-62-today/">after a rally yesterday</a>.</li>



<li>Expion360 (NASDAQ:<a href="https://investorplace.com/stock-quotes/xpon-stock-quote/">XPON</a>) stock is decreasing over 28% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318500633&amp;type=PDF&amp;symbol=XPON&amp;cdn=cc4a67ceca06cec716b8eaa852fb2069&amp;companyName=Expion360+Inc.&amp;formType=EFFECT&amp;formDescription=Notice+of+Effectiveness&amp;dateFiled=2024-08-06">with a public offering</a>.</li>



<li>Evotec (NASDAQ:<a href="https://investorplace.com/stock-quotes/evo-stock-quote/">EVO</a>) shares are falling more than 22% <a href="https://www.investing.com/news/stock-market-news/evotec-shares-crash-36-on-profit-warning-3558654">on a profit warning</a>.</li>



<li>CryoPort (NASDAQ:<a href="https://investorplace.com/stock-quotes/cyrx-stock-quote/">CYRX</a>) stock closes out our pre-market stock movers down over 20% after <a href="https://finance.yahoo.com/news/cryoport-inc-cyrx-reports-q2-230011376.html">missing Q2 estimates</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-aug-7th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Inogen: Upside Seems Limited After Big Move Up

Ventyx Biosciences: Ready To Escape "The Crash Cycle"

AMLX

ASRT

ATMVR

CLFD

CYRX

DZSI

EVAV

LUMN

NRGV

NVRO

OPAD

SCPX

SCYX

SHOP

SOFI

STEM

TLIS

UPST

VBIV

VCYT

XPON

ZCMD

Press Releases

Inogen to Report First Quarter 2024 Financial Results on May 7, 2024

Inogen Announces First Quarter 2024 Financial Results

Inogen Announces Publication of Study Demonstrating the Association of Portable Oxygen Therapy with Decreased Mortality and Increased Cost-Effectiveness Ratio

Inogen Strengthens Leadership Team with Appointment of New General Counsel and Executive Vice President, Business Development

Inogen to Report Second Quarter 2024 Financial Results on August 6, 2024

Inogen Announces Second Quarter 2024 Financial Results

Inogen Appoints Eric Pauls as Vice President of Sales, North America

Inogen Launches Rove 4 Portable Oxygen Concentrator, Delivering the Highest Oxygen Output in the Lightest Weight 4-Setting POC

Comments

Inogen

Vendite allo scoperto

Inogen (NASDAQ:INGN) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO